Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL).

Sokol K, Kartan S, Johnson WT, Alpdogan O, Nikbakht N, Haverkos BM, Gong J, Porcu P.

Front Oncol. 2019 Jun 13;9:509. doi: 10.3389/fonc.2019.00509. eCollection 2019.

2.

Special Considerations in the Treatment of Mycosis Fungoides.

Duffy R, Jennings T, Kartan S, Song A, Shi W, Porcu P, Alpdogan O, Sahu J.

Am J Clin Dermatol. 2019 Aug;20(4):571-578. doi: 10.1007/s40257-019-00431-z.

PMID:
30993584
3.

Primary central nervous system plasmablastic lymphoma in an HIV-positive patient.

Rhoades R, Gong J, Palmisiano N, Alpdogan O.

BMJ Case Rep. 2019 Mar 14;12(3). pii: e226755. doi: 10.1136/bcr-2018-226755.

PMID:
30872336
4.

Systemic therapy of cutaneous T-cell lymphoma (CTCL).

Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P.

Chin Clin Oncol. 2019 Feb;8(1):10. doi: 10.21037/cco.2019.01.02. Review.

5.

Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).

Shalabi D, Bistline A, Alpdogan O, Kartan S, Mishra A, Porcu P, Nikbakht N.

Chin Clin Oncol. 2019 Feb;8(1):11. doi: 10.21037/cco.2019.01.01. Epub 2019 Jan 9. Review.

6.

The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.

Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, Porcu P.

Chin Clin Oncol. 2019 Feb;8(1):3. doi: 10.21037/cco.2018.12.03. Epub 2019 Jan 9. Review.

7.

Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).

Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J, Porcu P.

Cancer Treat Res. 2019;176:83-98. doi: 10.1007/978-3-319-99716-2_4. Review.

PMID:
30596214
8.

Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review.

Johnson WT, Mukherji R, Kartan S, Nikbakht N, Porcu P, Alpdogan O.

Chin Clin Oncol. 2019 Feb;8(1):12. doi: 10.21037/cco.2018.10.03. Epub 2018 Oct 19. Review.

9.

Primary Cutaneous CD8+ T-cell Lymphoma, an Indolent and Locally Aggressive Form Mimicking Paronychia.

Beggs SM, Friedman BJ, Kornreich D, Okon L, Alpdogan O, Shi W, Sahu J.

Am J Dermatopathol. 2018 Apr;40(4):e52-e56. doi: 10.1097/DAD.0000000000001017.

PMID:
28984695
10.

Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation.

Pan J, Chen J, Filicko J, Grosso D, Nagurney M, Alpdogan O, Flomenberg N.

Case Rep Oncol. 2017 Jul 4;10(2):582-587. doi: 10.1159/000478001. eCollection 2017 May-Aug.

11.

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.

Bailey CP, Budak-Alpdogan T, Sauter CT, Panis MM, Buyukgoz C, Jeng EK, Wong HC, Flomenberg N, Alpdogan O.

Oncotarget. 2017 Jul 4;8(27):44366-44378. doi: 10.18632/oncotarget.17875.

12.

Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization.

Grosso D, Johnson E, Colombe B, Alpdogan O, Carabasi M, Filicko-O'Hara J, Gaballa S, Kasner M, Klumpp T, Martinez-Outschoorn U, Wagner JL, Weiss M, Wang Z, Flomenberg N.

Bone Marrow Transplant. 2017 Apr;52(4):615-619. doi: 10.1038/bmt.2016.324. Epub 2017 Jan 9. No abstract available.

PMID:
28067885
13.

Amlodipine-induced hypersensitivity reaction mimicking CD30(+) mycosis fungoides.

Gochoco A, Jones E, Soutendijk C, Alpdogan O, Shi W, Sahu J.

JAAD Case Rep. 2016 Aug 17;2(4):320-2. doi: 10.1016/j.jdcr.2016.06.013. eCollection 2016 Jul. No abstract available.

14.

Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia.

Siu SY, Jiang Q, Alpdogan O, Gochoco A, Gong J, Lee JB, Sahu J.

JAAD Case Rep. 2016 Jul 27;2(4):287-9. doi: 10.1016/j.jdcr.2016.05.008. eCollection 2016 Jul. No abstract available.

15.

A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.

Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Kraft WK, Leiby B, Martinez-Outschoorn U, O'Hara W, Pro B, Rudolph S, Sharma M, Wagner JL, Weiss M, Flomenberg N, Grosso D.

Biol Blood Marrow Transplant. 2016 Jan;22(1):141-8. doi: 10.1016/j.bbmt.2015.09.017. Epub 2015 Sep 28.

16.

Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.

Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F.

J Am Acad Dermatol. 2015 Jun;72(6):1010-5.e5. doi: 10.1016/j.jaad.2015.01.003.

PMID:
25981001
17.

Early laparoscopic cholecystectomy with continuous pressurized irrigation and dissection in acute cholecystitis.

Ozsan I, Yoldas O, Karabuga T, Yıldırım UM, Cetin HY, Alpdoğan O, Aydin U.

Gastroenterol Res Pract. 2015;2015:734927. doi: 10.1155/2015/734927. Epub 2015 Feb 24.

18.

Laparoscopic Appendectomy versus Mini-Incision Appendectomy in Patients with Lower Body Mass Index and Noncomplicated Appendicitis.

Özsan İ, Karabuğa T, Yoldaş Ö, Alpdoğan Ö, Aydın Ü.

Gastroenterol Res Pract. 2014;2014:138648. doi: 10.1155/2014/138648. Epub 2014 Dec 14.

19.

A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease.

Grosso D, Gaballa S, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Martinez-Outschoorn U, Wagner JL, O'Hara W, Rudolph S, Chervoneva I, Colombe B, Farley PC, Flomenberg P, Pro B, Sharma M, Shi W, Weiss M, Flomenberg N.

Biol Blood Marrow Transplant. 2015 Apr;21(4):646-52. doi: 10.1016/j.bbmt.2014.12.019. Epub 2014 Dec 23.

20.

Kaposi sarcoma mimicking multiple cherry angiomata clinically and histologically in a patient with Sezary syndrome: an unusual presentation.

Hannaway M, Zendell K, Osley K, Alpdogan O, Pro B, Sahu J.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):e35-7. doi: 10.1016/j.clml.2014.08.005. Epub 2014 Sep 21. No abstract available.

PMID:
25315973
21.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.

22.

Unclassified diffuse ductal cholangiocarcinoma; report of a case.

Aydın U, Ozsan I, Karabuğa T, Alpdoğan O, Ortaç R, Yoldaş O, Sahin E.

Case Rep Surg. 2014;2014:542849. doi: 10.1155/2014/542849. Epub 2014 Mar 4.

23.

Coexistence of gallbladder agenesis and cholangiocarcinoma: report of a case.

Yoldas O, Yazıcı P, Ozsan I, Karabuga T, Alpdogan O, Sahin E, Aydın U.

J Gastrointest Surg. 2014 Jul;18(7):1373-6. doi: 10.1007/s11605-014-2472-x. Epub 2014 Feb 12.

PMID:
24519037
24.

Recent advances in haploidentical stem cell transplantation.

Alpdogan O, Grosso D, Flomenberg N.

Discov Med. 2013 Oct;16(88):159-65. Review.

25.

Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT.

Sauter CT, Bailey CP, Panis MM, Biswas CS, Budak-Alpdogan T, Durham A, Flomenberg N, Alpdogan O.

Bone Marrow Transplant. 2013 Sep;48(9):1237-42. doi: 10.1038/bmt.2013.47. Epub 2013 Apr 29.

PMID:
23624821
26.

Advances in immune regulation in transplantation.

Alpdogan O.

Discov Med. 2013 Mar;15(82):150-9. Review.

27.

Haploidentical hematopoietic SCT increases graft-versus-tumor effect against renal cell carcinoma.

Budak-Alpdogan T, Sauter CT, Bailey CP, Biswas CS, Panis MM, Civriz S, Flomenberg N, Alpdogan O.

Bone Marrow Transplant. 2013 Aug;48(8):1084-90. doi: 10.1038/bmt.2013.9. Epub 2013 Feb 25.

PMID:
23435516
28.

Immune tolerance and transplantation.

Alpdogan O, van den Brink MR.

Semin Oncol. 2012 Dec;39(6):629-42. doi: 10.1053/j.seminoncol.2012.10.001. Review.

29.

Double haploidentical hematopoietic stem cell transplantation results in successful engraftment of bone marrow from both donors without graft-versus-host or graft-versus-graft effects.

Biswas CS, Sauter CT, Bailey CP, Rittenberg D, Luo X, Panis MM, Budak-Alpdogan T, Grosso D, Flomenberg N, Alpdogan O.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1808-18. doi: 10.1016/j.bbmt.2012.09.012. Epub 2012 Oct 16.

30.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

31.

Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.

Lu SX, Holland AM, Na IK, Terwey TH, Alpdogan O, Bautista JL, Smith OM, Suh D, King C, Kochman A, Hubbard VM, Rao UK, Yim N, Liu C, Laga AC, Murphy G, Jenq RR, Zakrzewski JL, Penack O, Dykstra L, Bampoe K, Perez L, Furie B, Furie B, van den Brink MR.

J Immunol. 2010 Aug 1;185(3):1912-9. doi: 10.4049/jimmunol.0903148. Epub 2010 Jul 9.

32.

Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao UK, Yim NL, Holland AM, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, Perales MA, van den Brink MR.

Blood. 2009 Feb 12;113(7):1574-80. doi: 10.1182/blood-2008-05-155697. Epub 2008 Nov 14.

33.

STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease.

Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, Gao GJ, Suh D, King C, Chow M, Smith OM, Hubbard VM, Bautista JL, Cabrera-Perez J, Zakrzewski JL, Kochman AA, Chow A, Altan-Bonnet G, van den Brink MR.

Blood. 2008 Dec 15;112(13):5254-8. doi: 10.1182/blood-2008-03-147322. Epub 2008 Oct 6.

34.

Organ-derived dendritic cells have differential effects on alloreactive T cells.

Kim TD, Terwey TH, Zakrzewski JL, Suh D, Kochman AA, Chen ME, King CG, Borsotti C, Grubin J, Smith OM, Heller G, Liu C, Murphy GF, Alpdogan O, van den Brink MR.

Blood. 2008 Mar 1;111(5):2929-40. doi: 10.1182/blood-2007-06-096602. Epub 2008 Jan 4.

35.

IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.

Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.

J Immunol. 2007 Aug 1;179(3):1669-80.

36.

Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation.

Goldberg GL, Alpdogan O, Muriglan SJ, Hammett MV, Milton MK, Eng JM, Hubbard VM, Kochman A, Willis LM, Greenberg AS, Tjoe KH, Sutherland JS, Chidgey A, van den Brink MR, Boyd RL.

J Immunol. 2007 Jun 1;178(11):7473-84.

37.

Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity.

Borsotti C, Franklin AR, Lu SX, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MR.

Blood. 2007 Jul 15;110(2):783-6. Epub 2007 Mar 29.

38.

DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation.

Perales MA, Diab A, Cohen AD, Huggins DW, Guevara-Patiño JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink MR.

J Immunol. 2006 Sep 15;177(6):4159-67.

39.

Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.

Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Smith OM, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, Perales MA, Rizzuto G, Menet E, Pamer EG, Heller G, Zúñiga-Pflücker JC, Alpdogan O, van den Brink MR.

Nat Med. 2006 Sep;12(9):1039-47. Epub 2006 Aug 27.

PMID:
16936725
40.

Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells.

Mayer-Kuckuk P, Doubrovin M, Bidaut L, Budak-Alpdogan T, Cai S, Hubbard V, Alpdogan O, van den Brink M, Bertino JR, Blasberg RG, Banerjee D, Gelovani J.

Cell Transplant. 2006;15(1):75-82.

PMID:
16700332
41.

Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration.

Alpdogan O, Hubbard VM, Smith OM, Patel N, Lu S, Goldberg GL, Gray DH, Feinman J, Kochman AA, Eng JM, Suh D, Muriglan SJ, Boyd RL, van den Brink MR.

Blood. 2006 Mar 15;107(6):2453-60. Epub 2005 Nov 22.

42.

Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

Waldman E, Lu SX, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.

Blood. 2006 Feb 15;107(4):1703-11. Epub 2005 Nov 15.

43.

IL-15: targeting CD8+ T cells for immunotherapy.

Diab A, Cohen AD, Alpdogan O, Perales MA.

Cytotherapy. 2005;7(1):23-35. Review.

PMID:
16040381
44.

CCR2 is required for CD8-induced graft-versus-host disease.

Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MR.

Blood. 2005 Nov 1;106(9):3322-30. Epub 2005 Jul 21.

45.

Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.

Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.

Blood. 2005 Nov 1;106(9):3285-92. Epub 2005 Jun 14. Erratum in: Blood. 2006 Jan 1;107(1):38.

46.

Ocular surface epithelia contain ABCG2-dependent side population cells exhibiting features associated with stem cells.

Budak MT, Alpdogan OS, Zhou M, Lavker RM, Akinci MA, Wolosin JM.

J Cell Sci. 2005 Apr 15;118(Pt 8):1715-24.

47.

IL-7 and IL-15: therapeutic cytokines for immunodeficiency.

Alpdogan O, van den Brink MR.

Trends Immunol. 2005 Jan;26(1):56-64. Review.

PMID:
15629410
48.

Strategies to enhance T-cell reconstitution in immunocompromised patients.

van den Brink MR, Alpdogan O, Boyd RL.

Nat Rev Immunol. 2004 Nov;4(11):856-67. Review.

PMID:
15516965
49.

Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.

Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, Bertino JR.

Cancer Gene Ther. 2004 Dec;11(12):767-73.

PMID:
15359285
50.

Supplemental Content

Loading ...
Support Center